Conference Coverage
Conference Coverage
Ocrelizumab safety update: Encouraging rates of serious infection, malignancy
No new safety signals were seen in the latest update from studies and postmarketing surveillance of MS patients treated with ocrelizumab.
Conference Coverage
Interferon treatment does not increase stroke risk in MS
Pooled data from 17 trials, as well as postmarketing surveillance data, show no increase in stroke risk with interferon treatment in MS patients...
Conference Coverage
EVOLVE-MS-1 study: ALKS 8700 shows promise for RRMS
LOS ANGELES – ALKS 8700, a novel prodrug of monomethyl fumarate, looks promising as an oral, disease-modifying treatment for RRMS.
Conference Coverage
Interim Results Show Efficacy for a Novel MS Drug
LOS ANGELES—Preliminary results for annualized relapse rate and MRI parameters support ALKS 8700 (also known as BIIB098) as an oral treatment for...
Conference Coverage
MRI Techniques Could Help Distinguish Between MS and Migraine
STOWE, VT—Some patients with migraine receive an inappropriate diagnosis of multiple sclerosis (MS). The two disorders share certain clinical and...
Conference Coverage
MS drugs in Medicare Part D: Higher tiers, less coverage, more prior authorizations
LOS ANGELES – The 2007-2016 analysis includes 11 drugs falling under Medicare Part D.
Video
VIDEO: AAN MS guidelines aim to help clinicians weigh expanding drug choices
LOS ANGELES – A “dramatically different” landscape of treatment options allows better tailoring to patients, authors say.
Conference Coverage
Eating Fish May Be Associated With a Reduced Risk of MS
LOS ANGELES—Eating fish at least once per week or eating fish one to three times per month, in addition to taking daily fish oil...
Conference Coverage
High Dose of Novel Compound Shows Promise for Relapsing-Remitting MS
SAN DIEGO—Patients with relapsing-remitting multiple sclerosis (MS) who received high doses of the novel human endogenous retrovirus-W antagonist...
Conference Coverage
What Is the Mechanism of Alemtuzumab-Induced Autoimmunity?
SAN DIEGO—The monoclonal antibody alemtuzumab can be an effective treatment for people living with multiple sclerosis (MS), but the agent is also...
